Jen L, PhD

Neurourology & overactive bladder: first International Functional and Reconstructive Urology Update August 29, 2024—Denver, Colorado
Therapeutic Advances in Urology
@journals.sagepub.com
@cuanschutz.bsky.social

journals.sagepub.com/doi/10.1177/...

#therapy #treatment #diagnosis #openaccess

Optimisation of a Cervical Cancer Screening Model Based on Self-Sampling for Human Papillomavirus Testing
@cancer-control.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#gynecologicalcancer #HPV #screeningprogram #oncology #openaccess

Controlled spatial and temporal release of neurotrophic growth factor from genetically modified tissue engineering living scaffolds
Journal of Tissue Engineering
@journals.sagepub.com
@upenn.edu

journals.sagepub.com/doi/10.1177/...

#nerveinjury #neurology #regeneration #openaccess

A prospective observational study of inflammatory mediators in cerebrospinal fluid after intraoperative radiotherapy of brain tumors
@tamedoncol.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#cancertreatment #inflammation #oncology #openaccess

Characteristics of KRAS WT pancreatic adenocarcinomas: results of a large French multicentric cohort
@tamedoncol.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#molecularoncology #genomics #pancreaticcancer #oncology #openaccess

Toward personalized therapeutic drug monitoring of ustekinumab in Crohn’s disease: influence of previous exposure to biologics
@tagastroenterol.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#inflammation #chronicdisease #gastroenterology #medicine #openaccess

CRISPRa genome-wide screen identifies novel gene targets for osteogenic cell engineering
Journal of Tissue Engineering
@journals.sagepub.com
@utah.edu

journals.sagepub.com/doi/10.1177/...

#bone #fracture #tissueregeneration #openaccess

Longitudinal Associations of Sedentary Behavior and Physical Activity With Sleep Duration and Quality in Individuals Living With and Beyond Colorectal Cancer
@cancer-control.bsky.social
@journals.sagepub.com
@maastrichtu.bsky.social

journals.sagepub.com/doi/10.1177/...

#cancersurvivorship

JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease
@tagastroenterol.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#IBD #chronicdisease #gastroenterology #medicine #openaccess

Impacts of a Novel Digital Education Module for Oncology Patients: A Prospective Experience
@cancer-control.bsky.social
@journals.sagepub.com

journals.sagepub.com/doi/10.1177/...

#patienteducation #patientcare #cancerresearch #openaccess

🔍 ctDNA analysis predicts recurrence & guides adjuvant therapy in CRC (stages I–IV).
✅ Post-op ctDNA positivity = 13× higher recurrence risk
✅ Longitudinal MRD improves sensitivity to 75%
Read more 👉https://buff.ly/ttlo1Wj
#CRC #ctDNA#Oncology

CDK4/6i resistance in HR+/HER2− BC
✅ Explores mechanisms: cell cycle dysregulation, signaling pathway changes
✅ Strategies: switching CDK4/6 drugs, novel endocrine combos, targeted therapy
Read more 👉 buff.ly/TNQGgFD
#BreastCancer #CDK46 #Oncology #DrugResistance

EVs-exRNA in bladder cancer: progress, challenges & future prospects for clinical application. Read more buff.ly/WX2dUSP
#Oncology #PrecisionMedicine

How safe and effective is efgartigimod in seronegative #MyastheniaGravis?
Results from a 6-month open-label study here:
journals.sagepub.com/doi/pdf/10.1...

🔬 New research:

A POLR1D-regulating SNP as a predictive marker candidate for platinum-based chemotherapy in gastrointestinal cancers

This GWAS highlights rs12876842 as a promising biomarker for platinum response. 🔗 Read more: buff.ly/Vu8EuM2

Top Read Papers on Natural Product Communications - November 2025

💡4. Systematic Evaluation of Rosemary Essential Oil in Aromatherapy Practice: A Review. Authored by: Dr. Milica Aćimović and Dr. Ana Miljkovic (Serbia).

journals.sagepub.com/doi/10.1177/...

Characterization of the intraspecies chimeric mouse brain at embryonic day 12.5
doi.org/10.1177/0963...
#brain #chimeric
@journals.sagepub.com

Can a mobile app facilitate digital documentation and communication in acute #stroke, and improve documentation rates and treatment times?
Stevens and colleagues designed a pilot study to find out:
journals.sagepub.com/doi/full/10....

2025 Metrics Update (November)
📄 Articles Published so far: 303
📄 Articles Accepted so far: 307
⏱️ Average Time to 1st Decision (peer-reviewed articles): 49 days
🌍 Author Diversity: 63 countries

Thanks to our team! 🙌

#NaturalProductsResearch

Ofatumumab is approved for adults with #MultipleSclerosis - but what is its utility in pediatric patients?
Wenlin Wu and colleagues present Case Series data from four pediatric patients:
journals.sagepub.com/doi/full/10....

How does TIME shape lung adenocarcinoma outcomes? This review explores scRNA-seq findings on heterogeneity, immunotherapy response, and drug resistance. Read more: buff.ly/0ktXclK

New real-life cohort study from Argentina compares the aspects of subcutaneous vs intravenous #natalizumab in #MultipleSclerosis:
journals.sagepub.com/doi/full/10....

Fresh evidence on IASLC residual tumor classification: Run linked to poorer survival in operable NSCLC. Full systematic review/meta-analysis: buff.ly/EoWjoVI #NSCLC #IASLC

‘They don’t have symptoms’: CAR-T therapies send autoimmune diseases into remission Engineered T cells that have been used to treat ulcerative colitis, rheumatoid arthritis and lupus show promising results.

We'll soon be covering the promise of CAR T-cells in autoimmune neurological disorders in our dedicated Special Collection, Guest Edited by Professor Marinos Dalakas.

In the meantime, you can learn about this emerging treatment modality for autoimmune disease here:
www.nature.com/articles/d41...

Proceedings from Group B Strep in Pregnancy & Babies Conference, Wednesday, May 14th 2025, virtual meeting, 2025

Check out highlights from the 2025 Group B Strep in Pregnancy & Babies Conference: new data spanning antimicrobial stewardship, epidemiology, diagnostics, prevention policies, virulence profiling, and next-gen sequencing for neonatal GBS.
journals.sagepub.com/doi/full/10....

📢 Real-world evidence
First-line pembrolizumab + chemo shows strong effectiveness and safety in advanced/recurrent ESCC:
✅ ORR: 60.9%
✅ Median OS: 17.3 months
Paclitaxel + platinum emerges as the best partner.
🔗 buff.ly/wb9uUJT
#ESCC #Immunotherapy #Oncology #RealWorldData

Delayed addition of PD-1/PD-L1 inhibitors to chemo may improve survival in ES-SCLC patients vs early start. Median OS: 24 vs 18.8 months after PSM. #Oncology #SCLC #Immunotherapy
buff.ly/TcJIvr4

🎉2025 Special Collections on Natural Product Communications 🎉
As 2025 wraps up, @willmanns.bsky.social and I are delighted to highlight the success of several Special Collections.
journals.sagepub.com/collection-i...
We are grateful to our guest editors, authors, and reviewers who made this possible

Sage Journals: Discover world-class research Subscription and open access journals from Sage, the world's leading independent academic publisher.

New from our Special Collection on Autoimmune Neurology and Paraneoplastic Neurologic Syndromes!

Immune checkpoint inhibitor therapy can lead to anti-Yo antibody development.

Farina et al describe the clinical and tumor features in some of these patients: journals.sagepub.com/doi/full/10....

Cell therapy for type 1 diabetes: Tracing historical progress and exploring emerging technologies
doi.org/10.1177/0963...
#diabetes
@journals.sagepub.com